Positives

• Patients in COVASTIL tolerated astegolimab well, with adverse events comparable to placebo and low immunogenicity (2.9%) PMC.
  
  
• The drug demonstrated clear pharmacodynamic activity on the IL-33/ST2 axis in hospitalized COVID pneumonia patients PubMed.
  
  

Negatives

• In the 396-patient COVASTIL Phase 2, astegolimab showed no significant difference from placebo in time to recovery or any secondary endpoint Critical Care Medicine.
  
  
• No long-COVID-specific outcomes were reported, leaving its post-acute role unproven PMC.
  
  

Hurdles & Side Effects

• Astegolimab remains investigational with no FDA approval for COVID or LC indications Respiratory Research.
  
  
• Access is limited to clinical trials in COPD or asthma, not LC patient populations PubMed.